Clinical Trial Search

Primary: Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 3; 0.5; 0; 3 Log inhibition

Primary: Number of Patients With Valid Recanalization Assessed by Magnetic Resonance Angiography (MRA) — 30; 40 participants

Primary: Number of Participants With Any Adverse Event (AE) — 282 participants

Primary: Mean Change From Baseline in Erythema at Weeks 1, 2, 4, 8, and 12 — 0.79; 0.76; 0.60; 0.47 units on a scale — p=0.9597

Primary: Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7. — -7.61; -6.67; -9.72; -5.22 days

Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale

Primary: Mean of 4 NRS Scores for 24 Hour Pain Intensity at Rest, Shown as Absolute Change From Baseline (i.e. a Decrease From the Baseline Value) — -1.2; -1.1 Units on a scale

Primary: Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-Week Treatment Period — -1.66; -1.17 units on a scale — p=<0.001

Primary: Erythema (Redness) — 0.94; 1.05; 1.42; 1.24 units on a scale — p=>0.05

Primary: Change From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at up to 10…

Primary: Comparison of Pre-implant Consonant-Nucleus-Consonant (CNC) Scores to Post-implant CNC Scores in Bilateral Users. — 4.0; 69.0 percent of words correct

Primary: Colonic Compliance — 16.60; 16.50 mm Hg

Primary: Change From Baseline in the Growth Velocity of Pre-pubescent Pediatric Participants to the End of the 52-week Double-blind (DB) Treatment Period — 5.46; 5.19 Centimeters…

Primary: Cigarette Smoking — 7 percent

Primary: Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA) — -0.69; -0.14 percent — p=0.170